The global Cancer Vaccines Market was valued at $4,278 million in 2020, and is projected to reach $7,430 million by 2027, registering a CAGR of 12.7% from 2020 to 2027.
Key Players in the Global Cancer Market are Advaxis Inc., Amgen Inc., Dynavax Technologies Corporation, Generex Biotechnology Corporation, and GlaxoSmithKline plc. (GSK), Immunocellular Therapeutics, Ltd, Merck & Co., Inc., Sanpower Group Co. Ltd. (Dendereon Corporation), UbiVac, Vaccinogen, Inc.
July 2020 The new vaccine was developed by a Mater Research team based at The Translational Research Institute in collaboration with The University of Queensland. The vaccine has the potential to treat a variety of blood cancers and malignancies and is a major breakthrough for cancer vaccinations. Researcher are hoping this vaccine could be used to treat blood cancers, such as myeloid leukaemia, non-Hodgkin's lymphoma, multiple myeloma, and pediatric leukaemias, plus solid malignancies including breast, lung, renal, ovarian, and pancreatic cancers, and glioblastoma. This new vaccine is comprised of human antibodies fused with tumor-specific protein, and we are investigating its capacity to target human cells while activating the memory of the tumor cells.
Some cancer treatment vaccines are made up of cancer cells, parts of cells, or pure antigens (certain proteins on the cancer cells). Sometimes a patient’s own immune cells are removed and exposed to these substances in the lab to create the vaccine. Once the vaccine is ready, it’s injected into the body to increase the immune response against cancer cells. Vaccines are often combined with other substances or cells called adjuvantsthat help boost the immune response even further.
In 2020 recent advances in immuno-oncology have opened previously unimaginable avenues to produce cancer vaccines. An increasing amount of research shows that immunotherapy could be a powerful weapon in the fight against cancer. Compared to traditional treatment methods that include surgery, chemotherapy, and/or radiotherapy, immunotherapy targets cancer cells more specifically, thus improving response rates and the quality of life of the patients. Cancer vaccines can be used to target tumor-associated antigens, tumor-specific antigens, cancer germline antigens, or virus-associated antigens. Cancer vaccines could be peptide/protein-based, cell-based, or DNA/RNA (gene)-based, with different types of adjuvants.
Agenus Inc. Sept 2020, an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to cancers and infections, presented preliminary results from two large clinical trials of more than 150 patients each at the European Society for Medical Oncology (ESMO) Virtual Congress 2020. Both trials were conducted in patients with recurrent/metastatic cervical cancer which has limited effective treatment options and disproportionately affects younger women. PD-L1 positive and negative tumors, these trials represent the largest trials of immuno-oncology therapies in relapsed cervical cancer to date and show that balstilimab and zalifrelimab may present meaningful new therapies for patients with cervical cancer. Advances in these agents offer renewed hope for patients who have limited treatment options.
New study, published on October 2, 2020 in Science Advances, demonstrates the use of charged nanoscale metal-organic frameworks for generating free radicals using X-rays within tumor tissue to kill cancer cells directly. Furthermore, the same frameworks can be used for delivering immune signaling molecules known as PAMPs to activate the immune response against tumor cells. By combining these two approaches into one easily administered "vaccine," this new technology may provide the key to better local and systemic treatment of difficult-to-treat cancers.
The global cancer vaccines market is segmented on the basis of technology, type, indication, end user, and region. By technology, the market is categorized into dendritic cells (DC) cancer vaccines, recombinant cancer vaccines, antigen/adjuvant cancer vaccines, and viral vector & DNA cancer vaccines. By type, it is bifurcated into preventive cancer vaccines and therapeutic cancer vaccines. By indication, it is classified into cervical cancer, prostate cancer, and others. By end user, it is divided into pediatric and adult. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. Asia-pacific is expected to expand at the highest CAGR during the forecast period.